LINC00707 accelerates the proliferation, migration and invasion of clear cell renal cell carcinoma.

OBJECTIVE: Long noncoding RNAs (lncRNAs) have been well concerned in tumor researches, which are believed to influence tumorigenesis and tumor progression. This study aims to uncover the role of LINC00707 in clear cell renal cell carcinoma (ccRCC) and the underlying mechanism. MATERIALS AND METHODS: Differentially expressed lncRNAs in ccRCC tissues and renal epithelial tissues were analyzed in The Cancer Genome Atlas (TCGA), and LINC00707 was screened out. Expression level of LINC00707 in ccRCC cell lines was determined as well. Regulatory effects of LINC00707 on influencing proliferative, migratory, and invasive abilities of 786-O and 769-P cells were assessed. At last, relative levels of epithelial-mesenchymal transition (EMT)-related genes E-cadherin and N-cadherin in 786-O and 769-P cells were detected by quantitative real time-polymerase chain reaction (qRT-PCR) and Western blot. RESULTS: LINC00707 was upregulated in ccRCC tissues and cell lines. Silence of LINC00707 attenuated proliferative, migratory, and invasive abilities of 786-O and 769-P cells. Moreover, knockdown of LINC00707 upregulated E-cadherin and downregulated N-cadherin in ccRCC cells at both mRNA and protein levels. CONCLUSIONS: LINC00707 is upregulated in ccRCC, which could promote cancer cells to proliferate, migrate, and invade. LINC00707 accelerates the progression of ccRCC by activating EMT pathway.

Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza).

1. The study aimed to investigate the pharmacokinetics of cryptotanshinone in a hydroxylpropyl-beta-cyclodextrin-included complex in dogs and rats. 2. Animals were administrated the inclusion complex of cryptotanshinone and the concentrations of cryptotanshinone and its major metabolite tanshinone IIA were determined by a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. 3. Cryptotanshinone in inclusion complex was absorbed slowly after an oral dose, and the C(max) and AUC(0-)(t) were dose-proportional. The bioavailability of cryptotanshinone in rats was (6.9% +/- 1.9%) at 60 mg kg(-1) and (11.1% +/- 1.8%) in dogs at 53.4 mg kg(-1). The t(1/2) of the compound in rats and dogs was 5.3-7.4 and 6.0-10.0 h, respectively. Cryptotanshinone showed a high accumulation in the intestine, lung and liver after oral administration, while the lung, liver and heart had the highest level following intravenous dose. Excretion data in rats showed that cryptotanshinone and its metabolites were mainly eliminated from faeces and bile, and the dose recovery rate was 0.02, 2.2, and 14.9% in urine, bile, and faeces, respectively. 4. The disposition of cryptotanshinone in an inclusion complex was dose-independent and the bioavailability was increased compared with that without cyclodextrin used to formulate the drug. Cryptotanshinone was distributed extensively into different organs. Excretion of cryptotanshinone and its metabolites into urine was extremely low, and they were mainly excreted into faeces and bile.

Effect of extract of Hirudo Medicinalis L. against adherence of calcium oxalate crystals to acid-injured bladder mucosa.

The effect of extract of Hirudo Medicinalis L. on preventing the adhesion of calcium oxalate crystals to 0.1 M hydrochloric acid-injured bladder urothelium of the rat was studied. It was found that in this species the extract coated to the bladder mucosa after it was instilled into the chemically injured bladder; and the adhesion of calcium oxalate crystals was prevented. In regard to the anti-adhesion property the Hirudo extract appears more effective than heparin, a documented glycosaminoglycan.